illumigene c. diff dna amplification assay (Meridian Bioscience)
90
Structured Review
Meridian Bioscience
illumigene c. diff dna amplification assay
Illumigene C. Diff Dna Amplification Assay, supplied by Meridian Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/illumigene+c%2E+diff/illumigene+c++difficile/pmc10303512-16-0-8
Average 90 stars, based on 1 article reviews
Illumigene C. Diff Dna Amplification Assay, supplied by Meridian Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/illumigene+c%2E+diff/illumigene+c++difficile/pmc10303512-16-0-8
Average 90 stars, based on 1 article reviews
illumigene c. diff dna amplification assay - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "Overview of current detection methods and microRNA potential in Clostridioides difficile infection screening"
Article Title: Overview of current detection methods and microRNA potential in Clostridioides difficile infection screening
Journal: World Journal of Gastroenterology
doi: 10.3748/wjg.v29.i22.3385
Figure Legend Snippet: Summary of Clostridioides difficile diagnostic tests
Techniques Used: Diagnostic Assay, Amplification, Enzyme Immunoassay
Figure Legend Snippet: Selected Food and Drug Administration-approved molecular assays
Techniques Used: Amplification, Luminex, Quantitative RT-PCR, Electrophoresis, DNA Amplification, Helicase-dependent Amplification, Polymerase Chain Reaction
Related Articles
other:Article Title: Clostridioides difficile toxin testing and positivity in Manitoba, Canada. Article Snippet: We assessed Clostridioides difficile toxin testing and positivity for all patients in Manitoba hospitals during June 2016–November 2018.. The testing rate was 30 per 10,000 patient bed days (95% confidence interval [CI], 30–31) and the incidence rate was 3.5 per 10,000 patient bed days (95% CI, 3.3–3.7).. The context of testing is essential to the interpretation of data among jurisdictions. (Received 28 January 2020; accepted 14 May 2020; electronically published 19 June 2020) Clostridioides difficile infection (CDI) remains a significant public health challenge in Manitoba and elsewhere in Canada.1,2 Rates of reported CDI have been increasing,3,4 and hospital and institutional outbreaks caused by CDI often cause significant disruption to the delivery of health services.2 Control of CDI is hampered by a lack of harmonized information on disease burden and time trends.5 The interpretation of surveillance data is difficult without a clear understanding of the intensity of testing. Article Title: n-3 and n-6 Fatty Acid Changes in the Erythrocyte Membranes of Patients with 658240251 Clostridium difficile Infection. Article Snippet: When the test came back positive for the antigen but negative for the toxin, the test for the C. diff. toxin was repeated with the ELISA C. diff. toxin A/B II test kit (TechLab Inc., Blacksburg, USA) or by genetic methods, |